Skip to content
Evigrade
CriticalSelective 5-HT1B/1D serotonin receptor agonist×Selective irreversible MAO-B inhibitor

Updated · Methodology

Mechanism

At recommended doses, selegiline inhibits monoamine oxidase type B (MAO-B) selectively and irreversibly, and above 10 mg a day it may lose this selectivity (selegiline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.4, 5.1 and 5.2). Monoamine oxidase type A (MAO-A) is the main enzyme that breaks down rizatriptan. A selective reversible MAO-A inhibitor raised the levels of rizatriptan and its active metabolite. The Spanish rizatriptan SmPC expects similar or greater effects with non-selective MAO inhibitors, both reversible and irreversible (rizatriptan SmPC, AEMPS, sections 4.5 and 5.2). The US Food and Drug Administration (FDA) rizatriptan label expects no pharmacokinetic interaction with selective MAO-B inhibitors (section 12.3). The selegiline SmPC contraindicates selegiline with serotonin agonists, rizatriptan among them, because of the risk of serious interactions that can lead to serotonin syndrome. The rizatriptan SmPC links its MAO inhibitor contraindication to the risk of coronary artery constriction and hypertensive crises (selegiline and rizatriptan SmPCs, AEMPS, section 4.5).

Symptoms

The prescribing information does not describe how this particular combination presents. However, the selegiline summary of product characteristics (SmPC) warns that serious interactions with serotonin agonists can lead to serotonin syndrome (Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). With monoamine oxidase (MAO) inhibitors, serotonin syndrome may occur during rizatriptan treatment: agitation, hallucinations, coma, fast heart rate, labile blood pressure, high temperature, overactive reflexes, poor coordination, nausea, vomiting and diarrhoea. Symptoms can start within minutes to hours of a new or higher dose of a serotonergic drug (rizatriptan label, US Food and Drug Administration, FDA, section 5.7). Rizatriptan itself can cause chest tightness and pain, sometimes intense and spreading to the throat, as well as palpitations and raised blood pressure (rizatriptan SmPC, AEMPS, sections 4.4 and 4.8). On rare occasions triptans have caused a marked rise in blood pressure, up to hypertensive crisis with acute impairment of organ systems, including in people with no history of hypertension (FDA rizatriptan label, section 5.8).

Management

The combination is contraindicated. The selegiline summary of product characteristics (SmPC) lists serotonin agonists among contraindicated combinations and names rizatriptan (Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). The rizatriptan SmPC contraindicates rizatriptan with monoamine oxidase (MAO) inhibitors and within 2 weeks of stopping them, without distinguishing them by enzyme type (AEMPS, sections 4.3 and 4.5). The US Food and Drug Administration (FDA) rizatriptan label is softer: it contraindicates MAO type A inhibitors and non-selective MAO inhibitors and expects no pharmacokinetic interaction with selective MAO type B inhibitors (sections 4, 7.5 and 12.3). The selectivity of selegiline depends on the dose: the recommended dose is 5–10 mg a day, and at higher doses it may lose its selectivity for MAO type B (selegiline SmPC, AEMPS, sections 4.2 and 4.4). Start rizatriptan no earlier than 2 weeks after stopping selegiline (rizatriptan SmPC, AEMPS, section 4.3). The FDA label sets this interval only after MAO type A inhibitors (section 4). No document says how long to wait before starting selegiline after rizatriptan. If the two drugs have nevertheless been taken together and signs of serotonin syndrome appear, stop rizatriptan (FDA rizatriptan label, section 5.7). Rizatriptan is also contraindicated on its own in moderately severe or severe hypertension and in untreated mild hypertension (rizatriptan SmPC, AEMPS, section 4.3). If chest pain and tightness suggest cardiac ischaemia, withhold further rizatriptan doses and assess the patient (rizatriptan SmPC, AEMPS, section 4.4).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Rizatriptan

Other interactions with Selegiline